Related references
Note: Only part of the references are listed.Challenges and future of HER2-positive gastric cancer therapy
Chenzhe Ma et al.
FRONTIERS IN ONCOLOGY (2023)
Metformin: update on mechanisms of action and repurposing potential
Marc Foretz et al.
NATURE REVIEWS ENDOCRINOLOGY (2023)
Metformin and Cancer, an Ambiguanidous Relationship
Sarah J. Skuli et al.
PHARMACEUTICALS (2022)
Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study
Jiaojiao Zheng et al.
BRITISH JOURNAL OF CANCER (2021)
Repurposing metformin for the treatment of gastrointestinal cancer
Ademar Dantas Cunha Junior et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
J. Silvio Gutkind et al.
JCI INSIGHT (2021)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Impact of Metformin Use on Survival in Patients with Gastric Cancer and Diabetes Mellitus Following Gastrectomy
Wai-Shan Chung et al.
CANCERS (2020)
Decreased expression of LKB1 is associated with epithelial-mesenchymal transition and led to an unfavorable prognosis in gastric cancer
Min Hu et al.
HUMAN PATHOLOGY (2019)
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Dan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
Md Sazzad Hassan et al.
SCIENTIFIC REPORTS (2019)
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
O. Nanni et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
Clinton Yam et al.
INVESTIGATIONAL NEW DRUGS (2019)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martin-Castillo et al.
Oncotarget (2018)
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
Kang-Seo Park et al.
BMB REPORTS (2018)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
Chao Wang et al.
ONCOTARGET (2017)
Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance
Wenhu Liu et al.
ONCOTARGET (2017)
Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex
Jessica J. Howell et al.
CELL METABOLISM (2017)
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
Jinkyoung Kim et al.
TUMOR BIOLOGY (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors
Jin-Soo Kim et al.
CANCER LETTERS (2015)
Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo
Shintaro Fujihara et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
Teraneh Z. Jhaveri et al.
ONCOTARGET (2015)
Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis
Jichang Wang et al.
ONCOTARGET (2015)
AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell
Gang Han et al.
CANCER BIOLOGY & THERAPY (2015)
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Hee Jeong Kim et al.
BREAST CANCER RESEARCH (2015)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
Kai Wang et al.
NATURE GENETICS (2014)
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford et al.
CANCER CELL (2013)
Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo
Kiyohito Kato et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Metformin and cancer: new applications for an old drug
Taxiarchis V. Kourelis et al.
MEDICAL ONCOLOGY (2012)
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+human breast cancer xenografts
Silvia Cufi et al.
ONCOTARGET (2012)
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of ErbB2/IGF-1 receptor interactions
Bolin Liu et al.
CELL CYCLE (2011)
Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo
C. Algire et al.
ONCOGENE (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy
A. Vazquez-Martin et al.
ANNALS OF ONCOLOGY (2009)
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
Alejandro Vazquez-Martin et al.
CELL CYCLE (2009)
Share Paper
